Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Head and Neck Neoplasms | 55 | 2022 | 475 | 7.750 |
Why?
|
Carcinoma, Squamous Cell | 50 | 2021 | 622 | 5.700 |
Why?
|
Quinazolines | 19 | 2015 | 243 | 2.780 |
Why?
|
Prostatic Neoplasms | 21 | 2021 | 964 | 2.660 |
Why?
|
ErbB Receptors | 19 | 2020 | 571 | 2.500 |
Why?
|
Radiotherapy, Intensity-Modulated | 8 | 2018 | 128 | 2.230 |
Why?
|
Oropharyngeal Neoplasms | 12 | 2019 | 51 | 2.150 |
Why?
|
Combined Modality Therapy | 43 | 2020 | 1174 | 2.140 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 17 | 2020 | 1402 | 2.080 |
Why?
|
Radiotherapy, Conformal | 10 | 2015 | 67 | 1.830 |
Why?
|
Cetuximab | 15 | 2020 | 99 | 1.800 |
Why?
|
Radiotherapy | 13 | 2019 | 187 | 1.790 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 15 | 2022 | 967 | 1.780 |
Why?
|
Antineoplastic Agents | 27 | 2017 | 1990 | 1.700 |
Why?
|
Chemoradiotherapy | 16 | 2020 | 201 | 1.600 |
Why?
|
Brachytherapy | 5 | 2016 | 103 | 1.490 |
Why?
|
Lung Neoplasms | 17 | 2022 | 2216 | 1.460 |
Why?
|
Radiosurgery | 11 | 2022 | 323 | 1.400 |
Why?
|
Diglycerides | 14 | 2016 | 60 | 1.360 |
Why?
|
Neoplasm Staging | 22 | 2018 | 1234 | 1.280 |
Why?
|
Radiotherapy Dosage | 22 | 2021 | 244 | 1.270 |
Why?
|
Neoplasm Proteins | 5 | 2020 | 415 | 1.080 |
Why?
|
Laryngeal Neoplasms | 5 | 2017 | 39 | 1.050 |
Why?
|
Chemotherapy, Adjuvant | 9 | 2020 | 369 | 1.040 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 7 | 2018 | 119 | 0.980 |
Why?
|
Phthalazines | 3 | 2020 | 47 | 0.950 |
Why?
|
Melanoma | 5 | 2018 | 709 | 0.940 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 5 | 2007 | 105 | 0.930 |
Why?
|
Biomarkers, Tumor | 9 | 2022 | 1076 | 0.920 |
Why?
|
Radiation Injuries | 7 | 2021 | 137 | 0.920 |
Why?
|
Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2020 | 76 | 0.890 |
Why?
|
DNA Repair | 4 | 2020 | 203 | 0.860 |
Why?
|
Diacylglycerol Kinase | 3 | 2016 | 5 | 0.860 |
Why?
|
Piperidines | 7 | 2015 | 169 | 0.860 |
Why?
|
Aged | 63 | 2019 | 20495 | 0.840 |
Why?
|
Piperazines | 3 | 2020 | 326 | 0.820 |
Why?
|
Thrombin | 9 | 2001 | 140 | 0.800 |
Why?
|
Immunotherapy | 4 | 2019 | 504 | 0.780 |
Why?
|
Humans | 141 | 2022 | 122796 | 0.770 |
Why?
|
Antibodies, Monoclonal | 10 | 2016 | 1306 | 0.770 |
Why?
|
Middle Aged | 62 | 2019 | 28563 | 0.770 |
Why?
|
Cisplatin | 13 | 2020 | 269 | 0.770 |
Why?
|
Neovascularization, Pathologic | 5 | 2006 | 292 | 0.760 |
Why?
|
Poly (ADP-Ribose) Polymerase-1 | 1 | 2020 | 40 | 0.760 |
Why?
|
Angiogenesis Inhibitors | 4 | 2006 | 223 | 0.750 |
Why?
|
Signal Transduction | 24 | 2019 | 4902 | 0.750 |
Why?
|
Xenograft Model Antitumor Assays | 13 | 2020 | 747 | 0.710 |
Why?
|
Phosphatidylcholines | 8 | 2016 | 136 | 0.700 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2016 | 60 | 0.690 |
Why?
|
Neoplasms | 10 | 2018 | 2235 | 0.670 |
Why?
|
Mice, Nude | 14 | 2020 | 668 | 0.670 |
Why?
|
Papillomavirus Infections | 5 | 2022 | 267 | 0.660 |
Why?
|
Glottis | 2 | 2017 | 21 | 0.660 |
Why?
|
Organ Sparing Treatments | 2 | 2015 | 31 | 0.650 |
Why?
|
Receptor, EphB4 | 4 | 2019 | 29 | 0.640 |
Why?
|
Survival Rate | 17 | 2019 | 1810 | 0.640 |
Why?
|
Stomatitis | 6 | 2021 | 14 | 0.620 |
Why?
|
Neoplasm Recurrence, Local | 12 | 2020 | 903 | 0.610 |
Why?
|
Mouth Neoplasms | 4 | 2019 | 79 | 0.600 |
Why?
|
Male | 74 | 2021 | 59639 | 0.600 |
Why?
|
Cell Line, Tumor | 23 | 2020 | 2904 | 0.600 |
Why?
|
Smokers | 1 | 2018 | 169 | 0.600 |
Why?
|
Unilamellar Liposomes | 1 | 2016 | 11 | 0.590 |
Why?
|
Enzyme Assays | 1 | 2016 | 24 | 0.590 |
Why?
|
Intracellular Membranes | 1 | 2016 | 78 | 0.580 |
Why?
|
Prognosis | 21 | 2022 | 3563 | 0.570 |
Why?
|
Molecular Targeted Therapy | 6 | 2019 | 361 | 0.570 |
Why?
|
Papillomaviridae | 7 | 2019 | 102 | 0.560 |
Why?
|
Aged, 80 and over | 25 | 2019 | 6845 | 0.560 |
Why?
|
Proton Therapy | 2 | 2017 | 10 | 0.560 |
Why?
|
Animals | 56 | 2021 | 34133 | 0.550 |
Why?
|
Radiation Oncology | 4 | 2018 | 75 | 0.540 |
Why?
|
Proportional Hazards Models | 15 | 2019 | 1184 | 0.540 |
Why?
|
Submandibular Gland | 1 | 2015 | 16 | 0.540 |
Why?
|
Skin Neoplasms | 2 | 2015 | 841 | 0.540 |
Why?
|
Mucositis | 4 | 2021 | 20 | 0.530 |
Why?
|
Radiation Tolerance | 6 | 2019 | 98 | 0.520 |
Why?
|
Female | 67 | 2021 | 63629 | 0.510 |
Why?
|
Prostate-Specific Antigen | 7 | 2016 | 160 | 0.510 |
Why?
|
Medically Uninsured | 1 | 2015 | 133 | 0.510 |
Why?
|
Ephrin-B2 | 3 | 2019 | 42 | 0.500 |
Why?
|
Nuclear Envelope | 3 | 2000 | 21 | 0.500 |
Why?
|
Treatment Outcome | 28 | 2019 | 9692 | 0.500 |
Why?
|
Adenosine Triphosphate | 1 | 2016 | 456 | 0.490 |
Why?
|
Cell Nucleus | 4 | 2004 | 598 | 0.480 |
Why?
|
Tumor Microenvironment | 4 | 2021 | 457 | 0.470 |
Why?
|
Esophagus | 2 | 2012 | 243 | 0.470 |
Why?
|
Insurance, Health | 1 | 2015 | 259 | 0.470 |
Why?
|
Disease-Free Survival | 15 | 2017 | 661 | 0.460 |
Why?
|
Epidermal Growth Factor | 8 | 2005 | 173 | 0.460 |
Why?
|
Androgen Antagonists | 4 | 2021 | 72 | 0.450 |
Why?
|
Clinical Trials as Topic | 9 | 2022 | 985 | 0.440 |
Why?
|
Kaplan-Meier Estimate | 12 | 2019 | 884 | 0.430 |
Why?
|
Phospholipids | 7 | 2000 | 211 | 0.430 |
Why?
|
Esophagitis | 1 | 2012 | 67 | 0.420 |
Why?
|
Phosphatidylinositols | 7 | 2000 | 68 | 0.420 |
Why?
|
Gene Expression Regulation, Neoplastic | 6 | 2020 | 1183 | 0.420 |
Why?
|
Remote Consultation | 1 | 2012 | 41 | 0.420 |
Why?
|
Mice | 31 | 2021 | 15888 | 0.410 |
Why?
|
Medicaid | 1 | 2015 | 416 | 0.410 |
Why?
|
Adult | 35 | 2019 | 32385 | 0.400 |
Why?
|
Antineoplastic Agents, Immunological | 4 | 2022 | 159 | 0.400 |
Why?
|
Radiation-Sensitizing Agents | 4 | 2019 | 38 | 0.400 |
Why?
|
Facial Neoplasms | 1 | 2011 | 17 | 0.390 |
Why?
|
Follow-Up Studies | 13 | 2019 | 4768 | 0.380 |
Why?
|
Lymph Nodes | 6 | 2019 | 466 | 0.380 |
Why?
|
Urinary Bladder | 2 | 2010 | 180 | 0.380 |
Why?
|
Comparative Effectiveness Research | 1 | 2011 | 142 | 0.370 |
Why?
|
Glycerides | 5 | 1993 | 16 | 0.370 |
Why?
|
Peptides, Cyclic | 3 | 2020 | 260 | 0.370 |
Why?
|
SEER Program | 8 | 2019 | 206 | 0.370 |
Why?
|
B7-H1 Antigen | 3 | 2021 | 151 | 0.360 |
Why?
|
Boronic Acids | 1 | 2010 | 43 | 0.360 |
Why?
|
Retrospective Studies | 20 | 2021 | 13433 | 0.360 |
Why?
|
Vascular Endothelial Growth Factors | 2 | 2009 | 68 | 0.360 |
Why?
|
Smad4 Protein | 2 | 2020 | 38 | 0.350 |
Why?
|
Pyrazines | 1 | 2010 | 79 | 0.350 |
Why?
|
Propensity Score | 5 | 2017 | 253 | 0.350 |
Why?
|
Pancreatic Neoplasms | 3 | 2019 | 803 | 0.350 |
Why?
|
Counseling | 1 | 2012 | 364 | 0.340 |
Why?
|
Adenoma | 1 | 2011 | 196 | 0.340 |
Why?
|
Carcinoma, Renal Cell | 1 | 2011 | 173 | 0.340 |
Why?
|
Neoplasm Grading | 5 | 2016 | 265 | 0.330 |
Why?
|
Feasibility Studies | 5 | 2015 | 780 | 0.330 |
Why?
|
Smad7 Protein | 3 | 2021 | 26 | 0.330 |
Why?
|
Radiotherapy, Adjuvant | 7 | 2017 | 191 | 0.330 |
Why?
|
ras Proteins | 1 | 2009 | 142 | 0.320 |
Why?
|
Fibroblasts | 8 | 2001 | 846 | 0.320 |
Why?
|
United States | 18 | 2019 | 13272 | 0.320 |
Why?
|
T-Lymphocytes, Regulatory | 3 | 2019 | 367 | 0.310 |
Why?
|
Nomograms | 2 | 2018 | 52 | 0.310 |
Why?
|
Organs at Risk | 4 | 2015 | 31 | 0.310 |
Why?
|
Cricetinae | 9 | 2001 | 269 | 0.300 |
Why?
|
Organophosphorus Compounds | 2 | 2005 | 78 | 0.300 |
Why?
|
Histocompatibility Antigens Class I | 2 | 2019 | 176 | 0.300 |
Why?
|
Proto-Oncogene Proteins | 2 | 2009 | 646 | 0.300 |
Why?
|
Kidney Neoplasms | 1 | 2011 | 331 | 0.290 |
Why?
|
Survival Analysis | 9 | 2019 | 1325 | 0.290 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2006 | 12 | 0.290 |
Why?
|
Mesoderm | 1 | 2007 | 148 | 0.280 |
Why?
|
Neoplasm Metastasis | 4 | 2018 | 563 | 0.280 |
Why?
|
Patient Acceptance of Health Care | 1 | 2012 | 707 | 0.280 |
Why?
|
Intestines | 1 | 2009 | 338 | 0.270 |
Why?
|
Technology, Radiologic | 1 | 2005 | 6 | 0.270 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2007 | 673 | 0.270 |
Why?
|
Antibodies, Monoclonal, Humanized | 7 | 2014 | 658 | 0.260 |
Why?
|
Mitogens | 4 | 2000 | 61 | 0.260 |
Why?
|
Dose-Response Relationship, Radiation | 5 | 2020 | 131 | 0.260 |
Why?
|
Protein-Tyrosine Kinases | 5 | 2015 | 442 | 0.260 |
Why?
|
Salivary Gland Neoplasms | 2 | 2016 | 32 | 0.250 |
Why?
|
Radiation, Ionizing | 6 | 2012 | 74 | 0.250 |
Why?
|
Maximum Tolerated Dose | 3 | 2015 | 186 | 0.250 |
Why?
|
Induction Chemotherapy | 2 | 2017 | 59 | 0.250 |
Why?
|
Kinetics | 9 | 2016 | 1658 | 0.240 |
Why?
|
Urinary Bladder Neoplasms | 3 | 2015 | 211 | 0.240 |
Why?
|
Stress, Psychological | 1 | 2012 | 1021 | 0.240 |
Why?
|
Type C Phospholipases | 2 | 1997 | 76 | 0.240 |
Why?
|
Mutation | 6 | 2013 | 3493 | 0.230 |
Why?
|
Transforming Growth Factor beta | 3 | 2021 | 468 | 0.230 |
Why?
|
DNA Mutational Analysis | 2 | 2018 | 390 | 0.230 |
Why?
|
Immunohistochemistry | 9 | 2019 | 1727 | 0.230 |
Why?
|
Neoplasms, Experimental | 2 | 2015 | 162 | 0.220 |
Why?
|
Disease Models, Animal | 8 | 2020 | 3799 | 0.220 |
Why?
|
Risk Assessment | 6 | 2019 | 3213 | 0.220 |
Why?
|
Phosphatidylserines | 3 | 2016 | 91 | 0.220 |
Why?
|
Tonsillar Neoplasms | 2 | 2015 | 8 | 0.220 |
Why?
|
Drug Synergism | 3 | 2020 | 346 | 0.220 |
Why?
|
Receptors, Thrombin | 2 | 2000 | 12 | 0.220 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2017 | 243 | 0.220 |
Why?
|
Apoptosis | 9 | 2020 | 2532 | 0.220 |
Why?
|
Taxoids | 4 | 2015 | 98 | 0.220 |
Why?
|
Circulating Tumor DNA | 1 | 2022 | 23 | 0.220 |
Why?
|
Hydrolysis | 7 | 2000 | 189 | 0.210 |
Why?
|
Membrane Lipids | 2 | 1994 | 88 | 0.210 |
Why?
|
Cricetulus | 6 | 2000 | 100 | 0.210 |
Why?
|
Transcriptome | 2 | 2018 | 774 | 0.210 |
Why?
|
Radiotherapy, Image-Guided | 2 | 2019 | 32 | 0.210 |
Why?
|
Prostatectomy | 3 | 2014 | 101 | 0.210 |
Why?
|
Databases, Factual | 6 | 2017 | 1287 | 0.210 |
Why?
|
DNA, Neoplasm | 2 | 2020 | 155 | 0.200 |
Why?
|
Rectum | 2 | 2014 | 158 | 0.200 |
Why?
|
Paclitaxel | 3 | 2012 | 202 | 0.200 |
Why?
|
Epithelial Cells | 1 | 2007 | 995 | 0.200 |
Why?
|
DNA End-Joining Repair | 1 | 2020 | 15 | 0.190 |
Why?
|
Proof of Concept Study | 1 | 2020 | 47 | 0.190 |
Why?
|
National Cancer Institute (U.S.) | 5 | 2019 | 43 | 0.190 |
Why?
|
Keratinocytes | 3 | 2017 | 238 | 0.190 |
Why?
|
Enzyme Inhibitors | 5 | 2005 | 836 | 0.190 |
Why?
|
Time Factors | 10 | 2017 | 6682 | 0.190 |
Why?
|
Models, Biological | 6 | 2018 | 1756 | 0.190 |
Why?
|
Neoplasm Transplantation | 4 | 2018 | 248 | 0.190 |
Why?
|
Clone Cells | 1 | 2020 | 255 | 0.190 |
Why?
|
Cohort Studies | 7 | 2021 | 5294 | 0.180 |
Why?
|
Chemoradiotherapy, Adjuvant | 2 | 2017 | 42 | 0.180 |
Why?
|
Radioimmunotherapy | 1 | 2019 | 12 | 0.180 |
Why?
|
Protein Synthesis Inhibitors | 1 | 2020 | 48 | 0.180 |
Why?
|
Cell Proliferation | 8 | 2020 | 2328 | 0.180 |
Why?
|
Carcinoma, Mucoepidermoid | 2 | 2017 | 16 | 0.180 |
Why?
|
Drosophila melanogaster | 2 | 2012 | 202 | 0.180 |
Why?
|
Carcinoma, Adenoid Cystic | 2 | 2017 | 17 | 0.180 |
Why?
|
Mice, Inbred BALB C | 5 | 2019 | 1245 | 0.180 |
Why?
|
Radiography | 4 | 2010 | 888 | 0.180 |
Why?
|
Chemokines, CXC | 1 | 2019 | 66 | 0.180 |
Why?
|
Lymphocyte Depletion | 1 | 2019 | 127 | 0.180 |
Why?
|
Tumor Escape | 1 | 2019 | 38 | 0.170 |
Why?
|
Phosphatidylethanolamines | 2 | 2016 | 66 | 0.170 |
Why?
|
Liver Neoplasms | 2 | 2018 | 546 | 0.170 |
Why?
|
Tongue Neoplasms | 2 | 2009 | 21 | 0.170 |
Why?
|
Genetic Heterogeneity | 1 | 2019 | 56 | 0.170 |
Why?
|
Receptor, EphB3 | 1 | 2018 | 4 | 0.170 |
Why?
|
Morpholines | 2 | 2018 | 111 | 0.170 |
Why?
|
Alphapapillomavirus | 2 | 2016 | 38 | 0.170 |
Why?
|
Hepatitis A Virus Cellular Receptor 2 | 1 | 2018 | 30 | 0.160 |
Why?
|
Chromosome Aberrations | 1 | 2019 | 136 | 0.160 |
Why?
|
Phosphorylation | 3 | 2016 | 1733 | 0.160 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 82 | 0.160 |
Why?
|
CTLA-4 Antigen | 1 | 2018 | 86 | 0.160 |
Why?
|
Hyperlipidemias | 1 | 2019 | 134 | 0.160 |
Why?
|
STAT3 Transcription Factor | 1 | 2019 | 193 | 0.160 |
Why?
|
Thyroid Carcinoma, Anaplastic | 1 | 2018 | 37 | 0.160 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2006 | 1213 | 0.160 |
Why?
|
Aminopyridines | 1 | 2018 | 86 | 0.160 |
Why?
|
Papillomavirus E7 Proteins | 1 | 2017 | 10 | 0.160 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 115 | 0.160 |
Why?
|
Patient Selection | 2 | 2019 | 717 | 0.160 |
Why?
|
Radiation Injuries, Experimental | 2 | 2018 | 24 | 0.150 |
Why?
|
Up-Regulation | 4 | 2019 | 891 | 0.150 |
Why?
|
Organ Specificity | 1 | 2018 | 287 | 0.150 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2010 | 1981 | 0.150 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2017 | 10 | 0.150 |
Why?
|
Paranasal Sinus Neoplasms | 1 | 2017 | 18 | 0.150 |
Why?
|
Gene Deletion | 1 | 2019 | 365 | 0.150 |
Why?
|
Nose Neoplasms | 1 | 2017 | 21 | 0.150 |
Why?
|
Phospholipase D | 2 | 1997 | 7 | 0.150 |
Why?
|
Cell Cycle | 5 | 2021 | 584 | 0.150 |
Why?
|
Transplantation, Heterologous | 4 | 2006 | 194 | 0.150 |
Why?
|
Prospective Studies | 7 | 2019 | 6704 | 0.150 |
Why?
|
Cell Line | 8 | 2001 | 2785 | 0.150 |
Why?
|
GTP-Binding Proteins | 1 | 1997 | 151 | 0.150 |
Why?
|
Neoplasms, Second Primary | 2 | 2008 | 91 | 0.150 |
Why?
|
Deoxycytidine | 2 | 2008 | 141 | 0.140 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2018 | 201 | 0.140 |
Why?
|
Radiodermatitis | 1 | 2016 | 7 | 0.140 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 2 | 2007 | 90 | 0.140 |
Why?
|
Drug Eruptions | 1 | 2016 | 28 | 0.140 |
Why?
|
Wound Healing | 1 | 2018 | 279 | 0.140 |
Why?
|
Neoplastic Stem Cells | 1 | 2020 | 340 | 0.140 |
Why?
|
Lymphatic Metastasis | 5 | 2019 | 310 | 0.140 |
Why?
|
Skin Ulcer | 1 | 2015 | 17 | 0.140 |
Why?
|
Antibodies | 1 | 2018 | 400 | 0.140 |
Why?
|
Cell Movement | 2 | 2018 | 929 | 0.140 |
Why?
|
Radiometry | 1 | 2015 | 45 | 0.140 |
Why?
|
Database Management Systems | 1 | 2016 | 57 | 0.140 |
Why?
|
Isoenzymes | 1 | 2016 | 303 | 0.140 |
Why?
|
Drug Screening Assays, Antitumor | 3 | 2012 | 190 | 0.140 |
Why?
|
Surface Properties | 1 | 2016 | 402 | 0.130 |
Why?
|
Colorectal Neoplasms | 2 | 2019 | 646 | 0.130 |
Why?
|
Neutrophils | 2 | 2019 | 1246 | 0.130 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2017 | 1260 | 0.130 |
Why?
|
Cell Transformation, Neoplastic | 1 | 1997 | 320 | 0.130 |
Why?
|
Radiation Protection | 1 | 2015 | 37 | 0.130 |
Why?
|
Thyroid Neoplasms | 1 | 2018 | 277 | 0.130 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2015 | 57 | 0.130 |
Why?
|
Deglutition Disorders | 2 | 2016 | 135 | 0.130 |
Why?
|
Carcinoma, Papillary | 1 | 2015 | 78 | 0.130 |
Why?
|
Neoplasm Invasiveness | 3 | 2017 | 472 | 0.130 |
Why?
|
Mammals | 1 | 2016 | 257 | 0.130 |
Why?
|
Hydroxamic Acids | 1 | 2015 | 80 | 0.130 |
Why?
|
Quality of Life | 4 | 2018 | 2457 | 0.130 |
Why?
|
Enzyme Activation | 4 | 2001 | 864 | 0.130 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 410 | 0.120 |
Why?
|
Protein Binding | 2 | 2016 | 2010 | 0.120 |
Why?
|
Analysis of Variance | 5 | 2019 | 1329 | 0.120 |
Why?
|
Stromal Cells | 1 | 2014 | 103 | 0.120 |
Why?
|
Tumor Burden | 4 | 2018 | 277 | 0.120 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2019 | 715 | 0.120 |
Why?
|
Fibroblast Growth Factor 2 | 2 | 2011 | 91 | 0.120 |
Why?
|
Cell Division | 3 | 2007 | 788 | 0.120 |
Why?
|
Platelet-Derived Growth Factor | 2 | 1990 | 85 | 0.120 |
Why?
|
Hedgehog Proteins | 1 | 2014 | 178 | 0.110 |
Why?
|
DNA Replication | 4 | 2000 | 214 | 0.110 |
Why?
|
Blotting, Western | 4 | 2013 | 1225 | 0.110 |
Why?
|
Multivariate Analysis | 5 | 2017 | 1531 | 0.110 |
Why?
|
Colorado | 2 | 2015 | 4325 | 0.110 |
Why?
|
Salvage Therapy | 2 | 2011 | 131 | 0.110 |
Why?
|
DNA, Viral | 2 | 2015 | 358 | 0.110 |
Why?
|
Phosphatidic Acids | 1 | 1992 | 10 | 0.110 |
Why?
|
Brain Neoplasms | 2 | 2018 | 1016 | 0.110 |
Why?
|
DNA Methylation | 1 | 2017 | 511 | 0.110 |
Why?
|
G1 Phase | 2 | 2005 | 71 | 0.110 |
Why?
|
Radiation-Protective Agents | 1 | 2012 | 28 | 0.110 |
Why?
|
Saccharomyces cerevisiae | 1 | 2016 | 507 | 0.110 |
Why?
|
Larynx | 1 | 2012 | 57 | 0.110 |
Why?
|
Metalloporphyrins | 1 | 2012 | 109 | 0.100 |
Why?
|
Adenocarcinoma | 2 | 2009 | 837 | 0.100 |
Why?
|
Diarrhea | 2 | 2010 | 181 | 0.100 |
Why?
|
Radiation Pneumonitis | 1 | 2011 | 26 | 0.100 |
Why?
|
Carbachol | 1 | 1991 | 21 | 0.100 |
Why?
|
Device Removal | 1 | 2012 | 127 | 0.100 |
Why?
|
Protein Kinase Inhibitors | 2 | 2010 | 833 | 0.100 |
Why?
|
Maytansine | 1 | 2011 | 13 | 0.100 |
Why?
|
Autocrine Communication | 1 | 2011 | 43 | 0.100 |
Why?
|
Telephone | 1 | 2012 | 160 | 0.100 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2011 | 64 | 0.100 |
Why?
|
Risk Factors | 6 | 2019 | 9381 | 0.100 |
Why?
|
Pilot Projects | 2 | 2015 | 1477 | 0.100 |
Why?
|
Tumor Cells, Cultured | 3 | 2020 | 904 | 0.100 |
Why?
|
Nerve Growth Factors | 1 | 1991 | 71 | 0.100 |
Why?
|
Drug Administration Schedule | 2 | 2010 | 757 | 0.100 |
Why?
|
Mohs Surgery | 1 | 2011 | 29 | 0.100 |
Why?
|
Second Messenger Systems | 1 | 1990 | 32 | 0.100 |
Why?
|
Flow Cytometry | 3 | 2019 | 1128 | 0.100 |
Why?
|
Palliative Care | 2 | 2010 | 632 | 0.100 |
Why?
|
Neoadjuvant Therapy | 3 | 2022 | 348 | 0.100 |
Why?
|
DNA Damage | 3 | 2020 | 368 | 0.100 |
Why?
|
Triazines | 1 | 2010 | 39 | 0.090 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2011 | 82 | 0.090 |
Why?
|
Caspase 3 | 1 | 2011 | 246 | 0.090 |
Why?
|
Arachidonic Acid | 3 | 1999 | 121 | 0.090 |
Why?
|
Bortezomib | 1 | 2010 | 49 | 0.090 |
Why?
|
In Situ Hybridization, Fluorescence | 4 | 2019 | 319 | 0.090 |
Why?
|
Lymphopenia | 1 | 2010 | 49 | 0.090 |
Why?
|
Nausea | 1 | 2010 | 110 | 0.090 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2015 | 75 | 0.090 |
Why?
|
Prostaglandin D2 | 1 | 2009 | 23 | 0.090 |
Why?
|
Lymphatic Irradiation | 1 | 2009 | 9 | 0.090 |
Why?
|
Cell Hypoxia | 1 | 2010 | 229 | 0.090 |
Why?
|
Urination Disorders | 1 | 2009 | 15 | 0.090 |
Why?
|
Neutropenia | 1 | 2010 | 134 | 0.090 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 2009 | 64 | 0.090 |
Why?
|
Palladium | 1 | 2009 | 12 | 0.090 |
Why?
|
Cystitis | 1 | 2009 | 22 | 0.090 |
Why?
|
Gene Expression Profiling | 4 | 2019 | 1625 | 0.090 |
Why?
|
Artifacts | 1 | 2010 | 130 | 0.090 |
Why?
|
Radioisotopes | 1 | 2009 | 36 | 0.090 |
Why?
|
Infusions, Intravenous | 1 | 2010 | 396 | 0.080 |
Why?
|
Exanthema | 1 | 2009 | 78 | 0.080 |
Why?
|
Polymerase Chain Reaction | 2 | 2009 | 1021 | 0.080 |
Why?
|
Cytotoxicity, Immunologic | 2 | 2019 | 204 | 0.080 |
Why?
|
Iodine Radioisotopes | 1 | 2009 | 128 | 0.080 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2009 | 128 | 0.080 |
Why?
|
Carcinoma | 2 | 2011 | 212 | 0.080 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2009 | 783 | 0.080 |
Why?
|
Antioxidants | 1 | 2012 | 581 | 0.080 |
Why?
|
Social Support | 1 | 2012 | 547 | 0.080 |
Why?
|
Receptor, ErbB-2 | 2 | 2015 | 321 | 0.080 |
Why?
|
Heterografts | 2 | 2019 | 132 | 0.080 |
Why?
|
Pelvis | 1 | 2009 | 94 | 0.080 |
Why?
|
Patient Satisfaction | 1 | 2012 | 632 | 0.080 |
Why?
|
Fatigue | 1 | 2010 | 311 | 0.080 |
Why?
|
Glutathione | 1 | 2009 | 327 | 0.080 |
Why?
|
Program Evaluation | 1 | 2012 | 880 | 0.080 |
Why?
|
Adaptation, Psychological | 1 | 2012 | 569 | 0.080 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2008 | 57 | 0.080 |
Why?
|
Gene Expression Regulation | 1 | 2017 | 2491 | 0.080 |
Why?
|
Fluorouracil | 1 | 2008 | 160 | 0.080 |
Why?
|
Bone Neoplasms | 2 | 2015 | 197 | 0.080 |
Why?
|
Predictive Value of Tests | 4 | 2017 | 1947 | 0.080 |
Why?
|
Rectal Neoplasms | 1 | 2008 | 122 | 0.080 |
Why?
|
Double-Blind Method | 1 | 2011 | 1711 | 0.070 |
Why?
|
Respiratory Mucosa | 1 | 2009 | 263 | 0.070 |
Why?
|
Cortactin | 1 | 2006 | 7 | 0.070 |
Why?
|
Gene Knockdown Techniques | 2 | 2019 | 322 | 0.070 |
Why?
|
Actin-Related Protein 2-3 Complex | 1 | 2006 | 8 | 0.070 |
Why?
|
Positron-Emission Tomography | 2 | 2006 | 308 | 0.070 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2006 | 67 | 0.070 |
Why?
|
Erythropoietin | 1 | 2007 | 82 | 0.070 |
Why?
|
Axilla | 1 | 2006 | 58 | 0.070 |
Why?
|
Nutritional Support | 1 | 2006 | 29 | 0.070 |
Why?
|
Xanthones | 1 | 2005 | 2 | 0.070 |
Why?
|
History, 21st Century | 1 | 2006 | 177 | 0.070 |
Why?
|
Neutrons | 1 | 2005 | 5 | 0.070 |
Why?
|
RNA Interference | 2 | 2018 | 473 | 0.070 |
Why?
|
Particle Accelerators | 1 | 2005 | 9 | 0.070 |
Why?
|
Imaging, Three-Dimensional | 1 | 2009 | 511 | 0.070 |
Why?
|
Resting Phase, Cell Cycle | 1 | 2005 | 15 | 0.070 |
Why?
|
History, 20th Century | 1 | 2006 | 288 | 0.070 |
Why?
|
Protein Kinase C | 2 | 2019 | 314 | 0.070 |
Why?
|
Sensitivity and Specificity | 3 | 2016 | 1855 | 0.060 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2004 | 27 | 0.060 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2013 | 358 | 0.060 |
Why?
|
Cross-Sectional Studies | 1 | 2015 | 4734 | 0.060 |
Why?
|
Electrons | 1 | 2005 | 73 | 0.060 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2005 | 537 | 0.060 |
Why?
|
Immunoenzyme Techniques | 1 | 2005 | 201 | 0.060 |
Why?
|
Mice, Inbred C57BL | 3 | 2021 | 5020 | 0.060 |
Why?
|
Mitosis | 2 | 2011 | 175 | 0.060 |
Why?
|
Trypanosoma | 2 | 1994 | 6 | 0.060 |
Why?
|
Glycosylphosphatidylinositols | 2 | 1994 | 10 | 0.060 |
Why?
|
Ki-67 Antigen | 1 | 2004 | 114 | 0.060 |
Why?
|
Disease Progression | 3 | 2018 | 2546 | 0.060 |
Why?
|
Socioeconomic Factors | 2 | 2019 | 1158 | 0.060 |
Why?
|
Young Adult | 2 | 2017 | 11094 | 0.060 |
Why?
|
Necrosis | 1 | 2004 | 238 | 0.060 |
Why?
|
Radiotherapy, High-Energy | 1 | 2003 | 12 | 0.060 |
Why?
|
Algorithms | 2 | 2015 | 1593 | 0.060 |
Why?
|
Biomarkers | 3 | 2019 | 3662 | 0.060 |
Why?
|
Biological Products | 2 | 2019 | 166 | 0.060 |
Why?
|
Biomedical Research | 1 | 2009 | 630 | 0.060 |
Why?
|
Etoposide | 2 | 2015 | 149 | 0.060 |
Why?
|
Genes, erbB-1 | 1 | 2002 | 18 | 0.060 |
Why?
|
Glioblastoma | 1 | 2005 | 262 | 0.060 |
Why?
|
Macrophages | 2 | 2019 | 1334 | 0.050 |
Why?
|
Reproducibility of Results | 3 | 2016 | 2977 | 0.050 |
Why?
|
Gene Products, tat | 1 | 2021 | 21 | 0.050 |
Why?
|
Diagnosis, Differential | 1 | 2006 | 1423 | 0.050 |
Why?
|
Protein Biosynthesis | 2 | 2015 | 408 | 0.050 |
Why?
|
Chemoprevention | 1 | 2002 | 99 | 0.050 |
Why?
|
Mitogen-Activated Protein Kinases | 2 | 2019 | 306 | 0.050 |
Why?
|
rhoA GTP-Binding Protein | 1 | 2001 | 80 | 0.050 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2001 | 115 | 0.050 |
Why?
|
Mass Screening | 1 | 2008 | 1095 | 0.050 |
Why?
|
Dogs | 1 | 2021 | 382 | 0.050 |
Why?
|
Logistic Models | 2 | 2017 | 1995 | 0.050 |
Why?
|
Cyclin D1 | 1 | 2000 | 63 | 0.050 |
Why?
|
Chromatography, Gas | 2 | 1990 | 32 | 0.050 |
Why?
|
Longitudinal Studies | 2 | 2018 | 2599 | 0.050 |
Why?
|
Incidence | 3 | 2016 | 2527 | 0.050 |
Why?
|
Peptide Chain Elongation, Translational | 1 | 2020 | 18 | 0.050 |
Why?
|
Androgens | 1 | 2021 | 169 | 0.050 |
Why?
|
Pain | 1 | 2006 | 746 | 0.050 |
Why?
|
Receptor, PAR-1 | 1 | 2000 | 22 | 0.050 |
Why?
|
Lipids | 1 | 2004 | 614 | 0.050 |
Why?
|
Choline | 2 | 1991 | 115 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 2 | 2011 | 2500 | 0.050 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 70 | 0.040 |
Why?
|
Pyrimidine Nucleosides | 1 | 2019 | 1 | 0.040 |
Why?
|
Cell Death | 2 | 2011 | 345 | 0.040 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2000 | 114 | 0.040 |
Why?
|
Administration, Oral | 1 | 2002 | 786 | 0.040 |
Why?
|
Immunologic Factors | 2 | 2016 | 228 | 0.040 |
Why?
|
Enteropeptidase | 1 | 1999 | 2 | 0.040 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2019 | 46 | 0.040 |
Why?
|
Myeloid-Derived Suppressor Cells | 1 | 2019 | 58 | 0.040 |
Why?
|
Forkhead Transcription Factors | 1 | 2019 | 188 | 0.040 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2019 | 169 | 0.040 |
Why?
|
Luminescence | 1 | 2018 | 35 | 0.040 |
Why?
|
Herpesvirus 1, Human | 1 | 2019 | 82 | 0.040 |
Why?
|
Computer Simulation | 2 | 2015 | 945 | 0.040 |
Why?
|
Choline Kinase | 1 | 1997 | 3 | 0.040 |
Why?
|
Lymph Node Excision | 1 | 2019 | 161 | 0.040 |
Why?
|
Rats | 3 | 2012 | 5426 | 0.040 |
Why?
|
Phosphatidate Phosphatase | 1 | 1997 | 5 | 0.040 |
Why?
|
Cell Transformation, Viral | 1 | 2017 | 22 | 0.040 |
Why?
|
Organoplatinum Compounds | 1 | 2017 | 41 | 0.040 |
Why?
|
GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 1997 | 16 | 0.040 |
Why?
|
Phospholipases A2 | 1 | 1997 | 77 | 0.040 |
Why?
|
Immunomodulation | 1 | 2018 | 91 | 0.040 |
Why?
|
DNA Primers | 1 | 1999 | 540 | 0.040 |
Why?
|
Fluorescent Antibody Technique | 1 | 2018 | 420 | 0.040 |
Why?
|
Transducin | 1 | 1997 | 41 | 0.040 |
Why?
|
Endothelium, Vascular | 1 | 2004 | 923 | 0.040 |
Why?
|
Immunologic Memory | 1 | 2019 | 321 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2017 | 141 | 0.040 |
Why?
|
Statistics, Nonparametric | 1 | 2018 | 416 | 0.040 |
Why?
|
Margins of Excision | 1 | 2017 | 30 | 0.040 |
Why?
|
Phospholipases A | 1 | 1997 | 102 | 0.040 |
Why?
|
Research Design | 1 | 2003 | 1002 | 0.040 |
Why?
|
Tumor Stem Cell Assay | 1 | 2016 | 36 | 0.040 |
Why?
|
CpG Islands | 1 | 2017 | 122 | 0.040 |
Why?
|
Variant Surface Glycoproteins, Trypanosoma | 2 | 1994 | 2 | 0.040 |
Why?
|
Oligonucleotides, Antisense | 1 | 1997 | 102 | 0.040 |
Why?
|
Otorhinolaryngologic Surgical Procedures | 1 | 2017 | 39 | 0.040 |
Why?
|
G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 41 | 0.040 |
Why?
|
Cells, Cultured | 4 | 2000 | 4162 | 0.040 |
Why?
|
Oligopeptides | 1 | 1999 | 255 | 0.040 |
Why?
|
Laryngectomy | 1 | 2016 | 20 | 0.040 |
Why?
|
Viral Core Proteins | 1 | 2016 | 21 | 0.040 |
Why?
|
Human Papillomavirus DNA Tests | 1 | 2015 | 3 | 0.040 |
Why?
|
Absorption, Radiation | 1 | 2015 | 3 | 0.040 |
Why?
|
Antigen Presentation | 1 | 2017 | 198 | 0.030 |
Why?
|
Causality | 1 | 2016 | 115 | 0.030 |
Why?
|
Skin | 2 | 2012 | 694 | 0.030 |
Why?
|
Lymphocytes | 1 | 2017 | 360 | 0.030 |
Why?
|
Neck Dissection | 1 | 2015 | 11 | 0.030 |
Why?
|
Insurance Coverage | 1 | 2017 | 218 | 0.030 |
Why?
|
Urothelium | 1 | 2015 | 33 | 0.030 |
Why?
|
Phosphatidylinositol Diacylglycerol-Lyase | 1 | 1994 | 5 | 0.030 |
Why?
|
Statistics as Topic | 1 | 2016 | 314 | 0.030 |
Why?
|
Severity of Illness Index | 2 | 2016 | 2784 | 0.030 |
Why?
|
Veratrum Alkaloids | 1 | 2014 | 18 | 0.030 |
Why?
|
Age Factors | 2 | 2016 | 3114 | 0.030 |
Why?
|
Zinc Finger Protein GLI1 | 1 | 2014 | 21 | 0.030 |
Why?
|
Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2014 | 37 | 0.030 |
Why?
|
Base Sequence | 1 | 1999 | 2186 | 0.030 |
Why?
|
3T3 Cells | 1 | 1994 | 141 | 0.030 |
Why?
|
Muscle, Smooth | 1 | 2015 | 159 | 0.030 |
Why?
|
Phosphoric Diester Hydrolases | 1 | 1994 | 47 | 0.030 |
Why?
|
Amino Acid Sequence | 1 | 1999 | 2123 | 0.030 |
Why?
|
Bevacizumab | 1 | 2015 | 127 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2016 | 581 | 0.030 |
Why?
|
Cell Fractionation | 1 | 1994 | 58 | 0.030 |
Why?
|
Fatty Acids | 2 | 1994 | 410 | 0.030 |
Why?
|
Mice, Transgenic | 1 | 2019 | 2079 | 0.030 |
Why?
|
HeLa Cells | 1 | 2015 | 609 | 0.030 |
Why?
|
Glycerol | 1 | 1994 | 90 | 0.030 |
Why?
|
Gene Expression | 1 | 2019 | 1506 | 0.030 |
Why?
|
Myristic Acids | 1 | 1993 | 9 | 0.030 |
Why?
|
Receptor, Notch2 | 1 | 2013 | 14 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2005 | 3264 | 0.030 |
Why?
|
Medicare | 1 | 2019 | 767 | 0.030 |
Why?
|
Gonanes | 1 | 2013 | 28 | 0.030 |
Why?
|
Smoking | 2 | 2014 | 1556 | 0.030 |
Why?
|
rac GTP-Binding Proteins | 1 | 2013 | 37 | 0.030 |
Why?
|
Histone Deacetylases | 1 | 2015 | 202 | 0.030 |
Why?
|
Epigenesis, Genetic | 1 | 2017 | 551 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2014 | 182 | 0.030 |
Why?
|
rac1 GTP-Binding Protein | 1 | 2013 | 58 | 0.030 |
Why?
|
Receptor, Notch1 | 1 | 2013 | 65 | 0.030 |
Why?
|
Neuropeptides | 1 | 2013 | 70 | 0.030 |
Why?
|
Chromatography, Thin Layer | 1 | 1992 | 23 | 0.030 |
Why?
|
Autoradiography | 1 | 1992 | 73 | 0.030 |
Why?
|
Alcohol Oxidoreductases | 1 | 2013 | 57 | 0.030 |
Why?
|
Erectile Dysfunction | 1 | 2012 | 37 | 0.030 |
Why?
|
Penis | 1 | 2012 | 38 | 0.030 |
Why?
|
Promoter Regions, Genetic | 1 | 2017 | 1188 | 0.030 |
Why?
|
Glioma | 1 | 2015 | 300 | 0.030 |
Why?
|
Testis | 1 | 2012 | 145 | 0.030 |
Why?
|
Group VI Phospholipases A2 | 1 | 2011 | 5 | 0.030 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2011 | 18 | 0.030 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2014 | 377 | 0.030 |
Why?
|
Models, Statistical | 1 | 2015 | 651 | 0.030 |
Why?
|
Thymidine | 1 | 1991 | 64 | 0.030 |
Why?
|
HCT116 Cells | 1 | 2011 | 71 | 0.020 |
Why?
|
Carboplatin | 1 | 2011 | 142 | 0.020 |
Why?
|
Hirudins | 1 | 1991 | 49 | 0.020 |
Why?
|
Camptothecin | 1 | 2011 | 100 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2013 | 182 | 0.020 |
Why?
|
Comorbidity | 1 | 2016 | 1600 | 0.020 |
Why?
|
Dinoprostone | 1 | 2011 | 193 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2017 | 813 | 0.020 |
Why?
|
Lipid Metabolism | 1 | 1994 | 482 | 0.020 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2010 | 25 | 0.020 |
Why?
|
Spindle Apparatus | 1 | 2011 | 89 | 0.020 |
Why?
|
Chymotrypsin | 1 | 1990 | 21 | 0.020 |
Why?
|
Retreatment | 1 | 2010 | 72 | 0.020 |
Why?
|
Larva | 1 | 2011 | 223 | 0.020 |
Why?
|
Erlotinib Hydrochloride | 1 | 2010 | 64 | 0.020 |
Why?
|
Prevalence | 1 | 2016 | 2442 | 0.020 |
Why?
|
tert-Butylhydroperoxide | 1 | 2009 | 10 | 0.020 |
Why?
|
Cytoprotection | 1 | 2009 | 58 | 0.020 |
Why?
|
Organ Size | 1 | 2010 | 474 | 0.020 |
Why?
|
Gastrostomy | 1 | 2010 | 93 | 0.020 |
Why?
|
NF-kappa B | 1 | 2013 | 676 | 0.020 |
Why?
|
Phenotype | 1 | 1997 | 3070 | 0.020 |
Why?
|
Computational Biology | 1 | 2013 | 601 | 0.020 |
Why?
|
Inositol Phosphates | 1 | 1988 | 28 | 0.020 |
Why?
|
Inositol | 1 | 1988 | 26 | 0.020 |
Why?
|
Premedication | 1 | 2008 | 41 | 0.020 |
Why?
|
Neck | 1 | 2009 | 90 | 0.020 |
Why?
|
Arachidonic Acids | 1 | 1988 | 57 | 0.020 |
Why?
|
Substrate Specificity | 1 | 2009 | 375 | 0.020 |
Why?
|
Capecitabine | 1 | 2008 | 46 | 0.020 |
Why?
|
Xerostomia | 1 | 2008 | 18 | 0.020 |
Why?
|
Postoperative Care | 1 | 2010 | 245 | 0.020 |
Why?
|
Pharyngeal Neoplasms | 1 | 2007 | 4 | 0.020 |
Why?
|
Benzimidazoles | 1 | 2009 | 142 | 0.020 |
Why?
|
Adolescent | 2 | 2017 | 18948 | 0.020 |
Why?
|
Movement | 1 | 2010 | 257 | 0.020 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2008 | 85 | 0.020 |
Why?
|
Ethanol | 1 | 1992 | 584 | 0.020 |
Why?
|
Remission Induction | 1 | 2008 | 246 | 0.020 |
Why?
|
Registries | 1 | 2016 | 2020 | 0.020 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2009 | 493 | 0.020 |
Why?
|
Health Transition | 1 | 2007 | 7 | 0.020 |
Why?
|
Hemoglobin A | 1 | 2007 | 19 | 0.020 |
Why?
|
Deoxycytidine Kinase | 1 | 2006 | 3 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2011 | 466 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2012 | 2501 | 0.020 |
Why?
|
Mouth Mucosa | 1 | 2007 | 81 | 0.020 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2008 | 184 | 0.020 |
Why?
|
Quality Assurance, Health Care | 1 | 2009 | 362 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2018 | 1994 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2013 | 2737 | 0.020 |
Why?
|
Enteral Nutrition | 1 | 2008 | 174 | 0.020 |
Why?
|
Transcription Factors | 1 | 2014 | 1616 | 0.020 |
Why?
|
Gene Amplification | 1 | 2006 | 98 | 0.020 |
Why?
|
Whole Body Imaging | 1 | 2006 | 25 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2017 | 5430 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2013 | 1384 | 0.020 |
Why?
|
Structure-Activity Relationship | 1 | 2006 | 536 | 0.020 |
Why?
|
Laminin | 1 | 2005 | 67 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 2006 | 518 | 0.020 |
Why?
|
Risk | 1 | 2008 | 890 | 0.020 |
Why?
|
Proteoglycans | 1 | 2005 | 111 | 0.020 |
Why?
|
Medical Oncology | 1 | 2007 | 231 | 0.020 |
Why?
|
Drug Combinations | 1 | 2005 | 292 | 0.020 |
Why?
|
Actins | 1 | 2006 | 409 | 0.020 |
Why?
|
Transfection | 1 | 2006 | 909 | 0.020 |
Why?
|
Global Health | 1 | 2007 | 352 | 0.020 |
Why?
|
Stearic Acids | 2 | 1994 | 14 | 0.020 |
Why?
|
Infant | 1 | 2017 | 8523 | 0.010 |
Why?
|
In Vitro Techniques | 1 | 2005 | 1130 | 0.010 |
Why?
|
Collagen | 1 | 2005 | 436 | 0.010 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2006 | 240 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2008 | 749 | 0.010 |
Why?
|
Child, Preschool | 1 | 2017 | 9755 | 0.010 |
Why?
|
Societies, Medical | 1 | 2007 | 741 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2009 | 1204 | 0.010 |
Why?
|
Weight Loss | 1 | 2006 | 663 | 0.010 |
Why?
|
Chromones | 1 | 2000 | 41 | 0.010 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2000 | 32 | 0.010 |
Why?
|
Child | 1 | 2017 | 19561 | 0.010 |
Why?
|
Cell Membrane | 1 | 1980 | 741 | 0.010 |
Why?
|
Peptides | 1 | 1980 | 893 | 0.010 |
Why?
|
Glycolipids | 1 | 1994 | 38 | 0.010 |
Why?
|
Radioisotope Dilution Technique | 1 | 1993 | 15 | 0.010 |
Why?
|
Tritium | 1 | 1993 | 71 | 0.010 |
Why?
|
Acetic Acid | 1 | 1993 | 17 | 0.010 |
Why?
|
Myristic Acid | 1 | 1993 | 10 | 0.010 |
Why?
|
DNA | 1 | 1980 | 1401 | 0.010 |
Why?
|
Acetates | 1 | 1993 | 100 | 0.010 |
Why?
|
Receptors, Cell Surface | 1 | 1980 | 368 | 0.000 |
Why?
|